NCT06132932View on ClinicalTrials.gov

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

January 3, 2023

Study Completion Date

January 3, 2023

Conditions
PIK3CA Mutation-Related Tumors
Interventions
DRUG

WX390

Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.

Trial Locations (1)

310000

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY